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Editorial on the Research Topic
Online Adaptive MR-Guided Radiotherapy
The radiotherapy field is rapidly evolving due to advances in radiation delivery and image guidance.
After the introduction of image guided radiotherapy (IGRT) two decades ago, the integration of
magnetic resonance imaging (MRI) with linear accelerators is the next logic step in IGRT. MR-
guided radiotherapy will lead to a paradigm shift in radiation oncology for multiple clinical
indications in the head and neck, thorax, abdomen and pelvis and opens new opportunities to
increase precision and to adapt the treatment (1–3).
In this Research Topic, the opportunities and challenges when using online adaptive MR-guided
radiotherapy will be described. Online adaptive magnetic resonance guided radiotherapy (MRgRT)
has the potential to improve both oncologic outcomes due to dose escalation and ultra-
hypofractionation, and decrease toxicity due to improved targeting accuracy by inter- and
intrafraction adaptation. However, the adaptive workflow is also time and resource intensive and
requires a drastic transformation of the offline and online radiotherapy workflow (4, 5).
Two MRI linear accelerator (MR-linac) systems to deliver MRgRT are commercially available
and have been clinically implemented across the world, other systems are being developed. The
technical specifications, opportunities and challenges of these MRgRT platforms (Elekta Unity and
Viewray MRIdian) are described by Thorwarth and Low. In order to reduce time and resources per
treatment fraction, automatization of most of the realtime MRgRT workflow is necessary. Before
routine implementation of these technical solutions, large standardized data sets including both
clinical and technical data are required for training and clinical validation of these models.
Although differences across both platforms are present and for few indications one system may
have advantages over the other, in general, both systems offer new functionality, including MR-
guidance and online adaptation when compared to conventional CT-guided radiotherapy. With
increasing implementation of MRgRT systems, the time window for high quality comparative
(randomized) trials is narrow, as described by Verkooijen and Henke. International collaborative
studies, preferably across platforms, are warranted to gain this timely evidence of the superiority of
MRgRT including patient-reported endpoints. For both systems, international research consortia
have been formed, where expert clinicians, physicists, methodologists, therapists and technologists
join forces for an evidence-based introduction of the technology and optimize the clinical impact
(6). Large international prospective data registries collecting clinical and technical data are being
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set-up aiming to include all patients treated at the MR-linac for
an evidence-based introduction of the technology and further
evolution of the technology (7).
When introducing complex innovations in radiation
oncology, a randomized controlled trial will not be the first
step after clinical implementation of the novel technology.
Several preparatory steps are required before comparative
studies can be initiated, especially with a continuously evolving
technology and evolving clinical application. The R-IDEAL
framework describes the steps towards an evidence-based
introduction of the new technology, with Phase 0
(Radiotherapy predicate studies), Phase 1 (Idea, first in man
study), Phase 2a (technical development studies), Phase 2b
(Exploration, early effectiveness in randomized studies), Phase
3 (Assessment in comparative studies) followed by Phase 4
(Long-term results) (8). Furthermore early Health Technology
Assessments of resource-intensive treatments would help
facilitate the reimbursement policy.
Besides the online adaptive approach and MR-guidance
during treatment, one of the unique aspects of MRgRT, is the
opportunity to perform biology-based image guided adaptive
radiotherapy (BIGART) as described by Van Houdt et al. By
acquiring biological images revealing metabolic and functional
data, focal dose escalation to the gross tumor volume within the
clinical target volume can be pursued, for example for prostate
cancer (9). Also this opens opportunities for ‘dose painting by
numbers’ within the tumor volume by using the heterogenic
characteristics within the tumor to deposit a differentiated dose
per voxel (10). MRgRT allows for daily quantitative imaging by
visualizing the tumor volume, shape and biology before and
during each radiotherapy fraction. Adaptation to changing
tumor shape and volume is already possible in present-day
MRgRT. In addition, imaging biomarkers need to be identified
that can predict treatment response early in the course of treatment,
which may eventually lead to response-adapted radiotherapy.
Again, large multicenter (standardized) imaging and clinical data
with multicenter and multiple tumor site validation are necessary,
which further strengthens the importance of collaboration in large
international data registries.
While BIGART may potentially impact all radiotherapy
(+/- systemic therapy) applications, it may be of particular
importance for the enhancement of radio-immunotherapy. The
immunogenic effect of radiation and its synergy with
immunotherapy, has been observed in several pre-clinical and
clinical studies and in pre-clinical studies the dose per fraction
seemed to be critical (11). As MRgRT allows for safe ultra-
hypofractionation and reduces the volume of normal tissue
irradiated by reduced treatment margins, radio-immunotherapy
delivered by MR-guidance may be a perfect match. Furthermore,
MRgRT facilitates visualization of the anatomical sites that should
or should not receive radiation, allowing for new clinical treatment
paradigms such as partial tumor irradiation or draining lymph
node sparing. Many questions need to be addressed such as
radiation dose, fractionation, timing of radiotherapy versus
immunotherapy, target volumes and biomarkers for response
prediction as highlighted by Hörner-Rieber et al. It should not
be a surprise, that international collaboration, standardization
and clinical and imaging data collection, including biomaterial,
will be the driving force towards optimization of this combination
treatment and proving its impact on oncological outcomes.
Since 2015, MR-linacs have been first used and were
implemented across the world from initial users to now dozens
of early adopters (12, 13). After the predicate and first in man
studies, for several clinical indications studies have been
performed on the early effectiveness, toxicity and patient
reported outcomes of MRgRT. In this editorial, several review
articles on MRgRT to treat tumors in the brain and spine, head
and neck, lung, esophagus, pancreas, kidney, liver, cervix,
prostate, bladder and rectum) are presented, including an
overview of the current evidence, clinical experience, state of
the art implementation of MR-guided radiotherapy and future
perspectives (Boldrini et al.; Boeke et al.; Tocco et al.; Crockett
et al.; Boldrini et al.; Maziero et al.; Lee et al.; Hall et al.; Keller
et al.; Hijab et al.; Portelance et al.).
Although clinicians see the great potential of MRgRT as a
logical next step in IGRT, and the first studies support the
potential benefit of MRgRT, randomized clinical evidence is not
yet available. A collaborative international effort (across platforms)
to set up comparative trials or prospective registry studies will be
necessary in the generation of high quality evidence on the benefits
of MRgRT over CT-guided radiotherapy.
With this Research Topic on online adaptive MR-guided
radiotherapy, we aim to give the reader an overview of the
ongoing advances in MR-guided radiotherapy to facilitate
institutes on the verge of implementation of MR-guided
radiotherapy into clinical practice. We thank all authors for
their excellent invited reviews and their willingness to collaborate
across platforms and share their expertise on MR-guided
radiotherapy. We believe that MR-guided radiotherapy can
have a tremendous impact on outcomes for patients for
multiple oncological indications. Advances in image-guided
adaptive and response-based radiotherapy are expected to
translate into improved oncologic outcomes, increasing the
number of indications to be treated by stereotactic
radiotherapy as a non-invasive treatment modality, reducing
toxicity and reducing the impact of cancer treatment on
quality of life. Therefore, we would like to make a ‘warm plea’
for international and across platforms collaboration of experts
involved in the multidisciplinary teams of MR-guided
radiotherapy to maximize the benefit of this paradigm shift in
radiation oncology and to prove its superior outcome and cost-
utility for the radiotherapeutic treatment of cancer patients
rather sooner than later.
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